Immunogenic Compositions for SARS-CoV-2 Vaccines Using MHC Class II Peptides
Summary
USPTO published patent application US20260097115A1 for immunogenic compositions containing MHC class II-binding peptides derived from SARS-CoV-2 translation products. The application covers vaccine compositions and methods for treating and preventing COVID-19. Inventors include researchers from Broad Institute and affiliated institutions.
What changed
USPTO published patent application US20260097115A1 for immunogenic compositions comprising MHC class II-binding peptides derived from SARS-CoV-2 translation products. The application covers vaccine compositions and methods for preventing and treating COVID-19 using these peptide-based immunogens.
Pharmaceutical companies and vaccine developers should monitor this application for competitive intelligence purposes. If granted, the patent could claim protection for specific peptide sequences and vaccine formulations binding to MHC class II molecules for SARS-CoV-2 immunity.
What to do next
- Monitor for patent grant status
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
IMMUNOGENIC COMPOSITIONS AND USE THEREOF
Application US20260097115A1 Kind: A1 Apr 09, 2026
Inventors
Shira Weingarten-Gabbay, Da-Yuan Chen, Siranush Sarkizova, Karl Clauser, Nir Hacohen, Steven Carr, Jennifer Abelin, Mohsan Saeed, Pardis Sabeti
Abstract
Immunogenic compositions comprising one or more peptides, wherein the one or more peptides: are capable of binding to Major Histocompatibility Complex (MHC) class II, and are derived from one or more translation products of SARS-CoV-2. Also provided include methods of treating and preventing diseases using the immunogenic compositions.
CPC Classifications
A61K 39/215 A61P 37/04 G01N 33/6818 G01N 33/6848 A61K 2039/53 G01N 2333/165
Filing Date
2025-12-09
Application No.
19413044
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.